A roundup of the latest pharma and healthcare news from Turkey including Omya’s new Turkish manufacturing site, Santa Farma’s fourth EU-GMP certification and the collaboration agreement between BioNTech and Turkey’s Koç University.
Omya production site in Turkey gains health authority approval (OutsourcingPharma)
Swiss company, Omya, has gained official Turkish Health Authority accreditation to produce GMP-compliant pharmaceutical ingredients. Together with its manufacturing sites in the USA and France, this is for Omya now the third fully certified plant supplying the pharma, nutraceutical, and food industries.
How Israel and Turkey are growing markets for clinical trials (Pharmaceutical Technology)
From diverse populations to supportive regulatory frameworks, Israel and Turkey are increasingly attracting multinational trials. We explore the range of factors that are making both countries appealing destinations to trial new medicinal products.
Santa Farma Pharmaceuticals Receives its 4th EU-GMP Certificate (Company website)
Santa Farma Pharmaceuticals was awarded EU-GMP (Good Manufacturing Practices) Certificate, which is required for marketing its products outside Turkey, for the fourth time as a result of the audits performed by the Croatian Health Authority (HALMED) in November 2022. The certificate which is issued for recognition of the products developed and manufactured by the company outside our country allows Santa Farma Pharmaceuticals to develop and register generic products for the European Union member states and other regulated markets.
Türkiye expects 30 pct upsurge in health tourism patients in 2023 (Hurriye Daily News)
Türkiye expects to receive over 1.8 million health tourists in 2023, with an increase of approximately 30 percent, the head of a tourism professional organization has said. “We expect to receive over 1.8 million health tourists in 2023 with an increase of approximately 30 percent,” said Firuz Bağlıkaya, president of the Association of Turkish Travel Agencies (TÜRSAB). “Likewise, we anticipate an increase in health tourism revenue.”
Koç University, BioNTech to cooperate on cancer research (Hurriye Daily News)
Germany-based biotechnology company BioNTech and Türkiye’s Koç University have signed a collaboration agreement that encompasses a series of clinical research, mainly cancer treatments. According to the agreement, clinical research will initially be conducted in the fields of cancer, neurological, and infectious diseases. In the following period, patients may volunteer for the trial stages of certain drugs.
Ministry to set up hospital for rare diseases (Hurriye Daily News)
Health Minister Fahrettin Koca has announced plans to establish a new hospital in Istanbul that will focus on the treatment of rare diseases, particularly through the application of cell and gene therapies. “We will have a facility on the same complex as the hospital that will manufacture the drugs required for these therapies. This way, we will be able to produce the drugs ourselves and carry out the treatment internally,” Koca stated during his address following a cabinet meeting on June 6.
